Estrella Immunopharma, Inc. Warrant financials
$0.0600−14.29%
Close Sep 23, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q2 '24 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$2.1M | -$2.3M | -$613.2K | -$4.8M | -$5.5M | -$2.1M | $3.4M | -$3.4M | -$3.9M | -$469.5K | -$1.0M |
| Net income | -$2.3M | -$2.3M | -$613.2K | -$4.8M | -$5.5M | -$2.1M | $3.4M | -$3.4M | -$4.0M | -$469.5K | -$1.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.05 | $-0.05 | $-0.02 | $-0.13 | $-0.15 | $-0.06 | $0.09 | $-0.09 | $-0.11 | $-0.01 | $-0.03 |
| EBITDA | -$2.1M | -$2.3M | -$613.2K | -$4.8M | -$5.5M | -$2.1M | $3.4M | -$3.4M | -$3.9M | -$469.5K | -$1.0M |
| Operating cash flow | -$1.8M | -$6.7M | -$177.5K | -$727.3K | -$414.9K | -$466.0K | $3.6M | -$2.2M | -$291.5K | -$4.2M | — |
| Free cash flow | -$1.8M | -$6.7M | -$177.5K | -$727.3K | -$414.9K | -$466.0K | $3.6M | -$2.2M | -$291.5K | -$4.2M | — |
| Diluted shares | 43.0M | 42.1M | 37.8M | 37.1M | 36.2M | 36.2M | 38.0M | 36.2M | 36.4M | 35.5M | 35.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $146.7K | $1.9M | $1.4M | $1.6M | $1.3M | $421.5K |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.8M | $3.7M | $3.2M | $3.5M | $3.0M | $2.4M |
| Total liabilities | $9.3M | $8.9M | $13.5M | $13.4M | $9.1M | $4.3M |
| Shareholders' equity | -$7.4M | -$5.3M | -$10.4M | -$9.8M | -$6.1M | -$1.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology